Limited coverage criteria – saxagliptin and saxagliptin-metformin

Last updated on April 3, 2025

 

Return to Special Authority drug list 

Generic name

saxagliptin

saxagliptin-metformin

Strength & form

2.5 mg, 5 mg saxagliptin tablet

2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg saxagliptin-metformin tablet

Special Authority criteria

Approval period

As part of a combination treatment for type 2 diabetes mellitus:

  • After inadequate glycemic control on maximum tolerated doses of dual therapy of metformin and a sulfonylurea OR dual therapy of metformin and an insulin

Indefinite

Practitioner exemptions

  • None

Special notes

  • Patients intolerant to a sulfonylurea may be considered for coverage
  • Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available through the Special Authority program)
  • Patients who meet the limited coverage criteria for saxagliptin automatically receive coverage for linagliptin

Special Authority request form(s)